Verastem Prices $250 Million Offering to Fund Cancer Drug Development
Key Facts
Verastem Oncology priced a securities offering with expected gross proceeds of approximately $250 million, according to its financing announcement on October 14, 2026. The offering includes the sale of 30,937,500 common shares at $8.00 per share, according to the underwriting agreement filed with the U.S. Securities and Exchange Commission.
The financing is intended to support the company's treatment programs, with proceeds to be used for "continued clinical development of product candidates," including its investigational VS-7375 program, as well as working capital and general corporate purposes. Verastem estimated net proceeds of about $234.7 million after underwriting discounts, commissions and estimated offering expenses, according to its regulatory filing.
The financing structure also includes pre-funded warrants for certain investors to purchase up to 312,503 shares, priced at $7.9999 per warrant. The company expected the offering to close on or about October 15, 2026, subject to customary closing conditions, according to the SEC filing.
The offering coincided with the announcement of preliminary clinical results for the investigational treatment at a dose of 900 mg daily, showing a confirmed objective response rate of 50%, or 4 of 8 pancreatic cancer patients receiving second-line treatment. In the broader group of patients receiving second-line or later treatment, the rate was 41%, or 9 of 22 patients, according to the company's statement.
The clinical development plans come as Verastem's research and development expenses rose to $41.3 million in the second quarter of 2026, from $24.8 million in the corresponding period of 2025, according to its quarterly results filed with the SEC.
On sales, the company's preliminary, unaudited estimates of net product revenue for the third quarter of 2026, which are subject to revision, ranged from $23.9 million to $24.1 million, compared with $11.2 million in the corresponding period of 2025. That range is below second-quarter 2026 revenue of $25.1 million, according to the earnings call transcript published by Investing.com.
Verastem estimated cash, cash equivalents and investments at about $172.8 million as of September 30, 2026, according to preliminary, unaudited figures preceding the October offering. That compares with $136.4 million at the end of the second quarter, according to results for that period, meaning the end-September estimate reflects liquidity before proceeds from the new financing.
As background to the company's commercial operations, the U.S. Food and Drug Administration granted accelerated approval on May 8, 2025, to the combination of avutometinib and defactinib, marketed as Avmapki Fakzynja Co-Pack. The approval covers adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, according to the agency's statement.
Alongside the financing and clinical update, Verastem announced the appointment of Michael Bailey as president and chief executive officer effective January 1, 2027, according to its leadership transition statement. The appointment follows Daniel Paterson's planned retirement from both roles, with Paterson remaining an adviser and a member of the company's board after handing over executive responsibilities to his successor.
Verastem shares rose 12.8% in premarket trading on the morning of the offering announcement, according to a report published by Investing.com on October 14, 2026. The early share price move coincided with the company's announcements on clinical data, financing and the executive leadership transition, according to the report published that morning.
On the next clinical step, Verastem said in its research presentation that it had reached alignment with the U.S. Food and Drug Administration on the protocol for a Phase III trial in first-line metastatic pancreatic cancer. The company plans to open the trial by the end of 2026, according to the target timeline announced in its October update.